Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $113.77 USD
Change Today -0.69 / -0.60%
Volume 1.0M
ZMH On Other Exchanges
New York
SIX Swiss Ex
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

zimmer holdings inc (ZMH) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/15 - $121.84
52 Week Low
08/8/14 - $94.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZIMMER HOLDINGS INC (ZMH)

zimmer holdings inc (ZMH) Related Businessweek News

No Related Businessweek News Found

zimmer holdings inc (ZMH) Details

Zimmer Holdings, Inc., together with its subsidiaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. It offers orthopaedic reconstructive devices that restore function lost due to disease or trauma in joints comprising knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons for the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. The company also provides related surgical products, such as surgical supplies and instruments to aid in orthopedic surgical procedures and post-operation rehabilitation; and other healthcare related services. It primarily serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, and healthcare dealers, as well as agents, healthcare purchasing organizations, or buying groups. The company was founded in 1927 and is headquartered in Warsaw, Indiana.

10,000 Employees
Last Reported Date: 02/23/15
Founded in 1927

zimmer holdings inc (ZMH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $934.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $539.9K
President of Europe, Middle East and Africa
Total Annual Compensation: $597.3K
President of Asia Pacific
Total Annual Compensation: $556.1K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $426.0K
Compensation as of Fiscal Year 2014.

zimmer holdings inc (ZMH) Key Developments

Zimmer Holdings, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM

Zimmer Holdings, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Dan Florin, CFO.

Zimmer Holdings, Inc. Announces Quarterly Dividend for Second Quarter of 2015, Payable on or About July 14, 2015

Zimmer Holdings, Inc. announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2015. The cash dividend of $0.22 per share will be paid on or about July 14, 2015, to stockholders of record as of the close of business on May 15, 2015.

Zimmer Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revised Earnings Guidance for the Year 2015; Provides Earnings Guidance for 2016

Zimmer Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company has posted Net Sales were $1,134.4 million against $1,161.5 million a year ago. Operating profit was $274.9 million against $300.1 million a year ago. Earnings before income tax were $231.8 million against $285.9 million a year ago. Net earnings were $176.8 million against $221.1 million a year ago. Diluted EPS was $1.02 against $1.29 a year ago. Net cash provided by operating activities were $91.5 million against $188.8 million a year ago. The decrease was driven primarily by the settlement of a pre-issuance hedge associated with recently completed senior notes offering. Additions to instruments were $62.4 million against $49.4 million a year ago. Additions to other property, plant and equipment was $34.4 million against $31.4 million a year ago. Purchases of investments were $152.6 million against $600.7 million a year ago. Investments in other assets were $3.0 million. Adjusted diluted EPS was $1.58 against $1.60 a year ago. Adjusted operating profit in the quarter amounted to $386.2 million. Adjusted net earnings were $272.8 million for the first quarter, a decrease of 0.6% compared to the prior year. Based upon the continued strengthening of the U.S. dollar, the company has updated its full-year 2015 standalone adjusted earnings guidance. The company now expects adjusted diluted earnings per share on a standalone basis to be in a range of $6.30 to $6.40. This compared to prior full-year 2015 guidance of $6.50 to $6.60. Additionally, changes in currency rates are also expected to negatively impact Biomet earnings, which the company expects to be partially offset by greater synergies from the pending merger than had previously been contemplated in the company's guidance. Net annual operating earnings synergies connected with the pending merger are now anticipated to reach $350 million by year three following the closing of the transaction. This compares to prior guidance of net annual synergies of $270 million by the third year post-closing. Consequently, the company now expects accretion from the pending merger with Biomet to contribute between $0.95 and $1.05 to adjusted diluted earnings per share in the first 12 months following the closing of the transaction. This accretion guidance was previously a range of $1.05 to $1.15. The company expects foreign currency translation will decrease reported revenues for the full year by 6.5% to 7%. The company expects revenues to grow organically between 1.5% and 2.5% over pro forma 2014 revenues or between $6.17 billion and $6.2 billion. For the year 2016, the company's adjusted diluted earnings per share should grow at mid-teens or higher rate compared to 2015 guidance of $6.60 to $6.80.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZMH:US $113.77 USD -0.69

ZMH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $68.33 USD +0.50
Hospira Inc $88.27 USD -0.04
Intuitive Surgical Inc $495.27 USD +0.32
Smith & Nephew PLC 1,134 GBp -6.00
St Jude Medical Inc $74.27 USD -0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation ZMH Industry Range
Price/Earnings 29.0x
Price/Sales 4.2x
Price/Book 2.9x
Price/Cash Flow 29.1x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIMMER HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at